Pesquisar
Biohaven Ltd
BHVNAdicionar à lista de desejos
15.760USD
+0.880+5.91%
Fechamento 07/01, 16:00（ET）Cotações atrasadas em 15 min
2.37BValor de mercado
PerdaP/L TTM
Mais detalhes de Biohaven Ltd Empresa
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
Informações de Biohaven Ltd
Código da empresaBHVN
Nome da EmpresaBiohaven Ltd
Data de listagemSep 23, 2022
CEOCoric (Vlad)
Número de funcionários256
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 23
Endereço215 Church Street
CidadeNEW HAVEN
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal06510
Telefone12034040410
Sitehttps://www.biohaven.com/
Código da empresaBHVN
Data de listagemSep 23, 2022
CEOCoric (Vlad)
Executivos da empresa Biohaven Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
2.02M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
195.65K
+0.28%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
67.72K
+45.11%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
Dr. Irina Antonijevic, M.D., Ph.D.
Dr. Irina Antonijevic, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Kishen (Kishan) Mehta
Mr. Kishen (Kishan) Mehta
Director
Director
--
--
Mr. John W. Childs
Mr. John W. Childs
Independent Director
Independent Director
--
--
Ms. Kimberly Gentile
Ms. Kimberly Gentile
Senior Vice President of Clinical Operations
Senior Vice President of Clinical Operations
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
2.02M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
195.65K
+0.28%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
67.72K
+45.11%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
Perguntas frequentes
Quem são os cinco principais acionistas de Biohaven Ltd?
Os cinco principais acionistas de Biohaven Ltd são: Dr. Gregory Hugh (Greg) Bailey, M.D.
Quantas instituições possuem ações da Biohaven Ltd (BHVN)?
Em 2026Q1, 610 instituições possuíam ações da Biohaven Ltd, com valor de mercado aproximado de 138.20M, representando 91.79% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 37866485.00.